Correlation Between Morgan Stanley and BioNTech

Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and BioNTech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and BioNTech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Morgan Stanley Direct and BioNTech SE, you can compare the effects of market volatilities on Morgan Stanley and BioNTech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of BioNTech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and BioNTech.

Diversification Opportunities for Morgan Stanley and BioNTech

0.45

Correlation Coefficient

Morgan Stanley  BioNTech

Very weak diversification

The 3 months correlation between Morgan and BioNTech is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley Direct and BioNTech SE in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioNTech SE and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley Direct are associated (or correlated) with BioNTech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioNTech SE has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and BioNTech go up and down completely randomly.

Pair Corralation between Morgan Stanley and BioNTech

Given the investment horizon of 90 days Morgan Stanley is expected to generate 1.49 times less return on investment than BioNTech. But when comparing it to its historical volatility, Morgan Stanley Direct is 3.69 times less risky than BioNTech. It trades about 0.33 of its potential returns per unit of risk. BioNTech SE is currently generating about 0.13 of returns per unit of risk over similar time horizon. If you would invest  10,000  in BioNTech SE on September 13, 2024 and sell it today you would earn a total of  990.00  from holding BioNTech SE or generate 9.9% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	95.45%
Values	Daily Returns

Morgan Stanley Direct  vs.  BioNTech SE

Morgan Stanley Direct

Risk-Adjusted Performance

12 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Morgan Stanley Direct are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite quite weak fundamental indicators, Morgan Stanley may actually be approaching a critical reversion point that can send shares even higher in January 2025.

BioNTech SE

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days BioNTech SE has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, BioNTech is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders.

Pair Trading with Morgan Stanley and BioNTech

The main advantage of trading using opposite Morgan Stanley and BioNTech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, BioNTech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will offset losses from the drop in BioNTech's long position.

The idea behind Morgan Stanley Direct and BioNTech SE pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.